Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ROCHE VERSED WHOLESALER PRICE INCREASED 9.5%

Executive Summary

ROCHE VERSED WHOLESALER PRICE INCREASED 9.5% on July 1 for the most popular dosage, the 5 mg/ml 1 ml vial. A Roche Labs' notice sent to wholesalers July 1 cites higher prices for seven of the eight Versed (midazolam) dosage forms. The increases ranged from 9.5% to 19.5%. The last time Roche Labs raised Versed prices was eight months ago, in October 1990. The highest increase in Versed's average wholesale price was for a box of 10 Versed 5 mg/ml 10 ml multidose vials: $ 671.69 as of July 1. The prices for four other Versed dosages rose 14.9%, with the new prices ranging from $ 143.90 for 2 ml unit dose vials of 5 mg/ml to $ 346.70 for 5 ml multidose vials (both in boxes of 10). Of the 45 drugs included on Roche's price list, only three were not subject to price increases -- Roche's biggest seller, the hospital antibiotic Rocephin (ceftriaxone sodium); and the anti- cancer drugs Roferon-A (interferon alfa-2a); and fluorouracil. Other major Roche drugs with higher prices as of July 1 are Accutane, Bactrim and Bumex, which now cost wholesalers an additional 9.5%. The AWP for the 15 dosage forms of Valium is up 6%, as is the price for the non-barbiturate sedative Dalmane. Valium prices now range from $ 15.78 per 5 mg/ml 10 ml vial to $ 432.25 for 500 10 mg tablets. The top Dalmane price is $ 258.50 for 500 30 mg tablets.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel